|
Re: NASH is a $35 Billion US/year market
|
3
|
Resverlogix Corp.
|
Jan 02, 2019 11:04AM
|
|
Re: NASH is a $35 Billion US/year market
|
2
|
Resverlogix Corp.
|
Dec 31, 2018 09:22PM
|
|
Re: NASH is a $35 Billion US/year market
|
2
|
Resverlogix Corp.
|
Dec 31, 2018 12:24PM
|
|
Re: Just reviewed the Sept 12, 2018 Slide Deck posted on the web site
|
1
|
Resverlogix Corp.
|
Dec 31, 2018 12:11AM
|
|
Re: Adjudication
|
4
|
Resverlogix Corp.
|
Dec 28, 2018 05:26PM
|
|
More BET Publications and New Indications
|
1
|
Zenith Epigenetics
|
Dec 28, 2018 05:14PM
|
|
Re: Adjudication
|
4
|
Resverlogix Corp.
|
Dec 28, 2018 02:52PM
|
|
Re: Third Eye Loan
|
2
|
Resverlogix Corp.
|
Dec 28, 2018 12:13PM
|
|
Re: Third Eye Loan
|
3
|
Resverlogix Corp.
|
Dec 28, 2018 11:16AM
|
|
Re: Novartis & Pfizer withdraw drug application in Europe
|
3
|
Resverlogix Corp.
|
Dec 23, 2018 11:01AM
|
|
Re: Holding steady
|
3
|
Resverlogix Corp.
|
Dec 22, 2018 09:37PM
|
|
Re: Holding steady
|
4
|
Resverlogix Corp.
|
Dec 22, 2018 08:28AM
|
|
Re: Holding steady
|
3
|
Resverlogix Corp.
|
Dec 21, 2018 08:35PM
|
|
Holding steady
|
4
|
Resverlogix Corp.
|
Dec 21, 2018 04:36PM
|
|
Coronary Artery Calcium Score
|
6
|
Resverlogix Corp.
|
Dec 21, 2018 10:34AM
|
|
Re: Third Eye and Topline
|
2
|
Resverlogix Corp.
|
Dec 20, 2018 02:30PM
|
|
Re: Third Eye and Topline
|
3
|
Resverlogix Corp.
|
Dec 20, 2018 11:57AM
|
|
Re: IR reply...
|
3
|
Resverlogix Corp.
|
Dec 19, 2018 07:42PM
|
|
Re: Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
|
1
|
Resverlogix Corp.
|
Dec 19, 2018 09:02AM
|
|
Resverlogix Announces Eighth Positive Data Safety Monitoring Board Recommendation For Phase 3 Study of Apabetalone
|
2
|
Resverlogix Corp.
|
Dec 19, 2018 08:53AM
|
